Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Total Liabilities: 2010-2024

Historic Total Liabilities for China Pharma Holdings (CPHI) over the last 15 years, with Dec 2024 value amounting to $7.1 million.

  • China Pharma Holdings' Total Liabilities rose 7.98% to $7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.5 million, marking a year-over-year increase of 7.98%. This contributed to the annual value of $7.1 million for FY2024, which is 20.80% down from last year.
  • China Pharma Holdings' Total Liabilities amounted to $7.1 million in FY2024, which was down 20.80% from $9.0 million recorded in FY2023.
  • Over the past 5 years, China Pharma Holdings' Total Liabilities peaked at $16.6 million during FY2021, and registered a low of $7.1 million during FY2024.
  • Over the past 3 years, China Pharma Holdings' median Total Liabilities value was $9.0 million (recorded in 2023), while the average stood at $9.9 million.
  • In the last 5 years, China Pharma Holdings' Total Liabilities grew by 26.83% in 2021 and then tumbled by 33.20% in 2023.
  • China Pharma Holdings' Total Liabilities (Yearly) stood at $13.1 million in 2020, then grew by 26.83% to $16.6 million in 2021, then dropped by 18.87% to $13.5 million in 2022, then plummeted by 33.20% to $9.0 million in 2023, then dropped by 20.80% to $7.1 million in 2024.